DIAFIR

DIAFIRTM has been established to develop, manufacture and market new solutions using innovative infrared optics developed by Rennes University in chalcogenide glass. These optics can be lenses or fiber optics. They have one aim: to provide easily unique information accessible in the mid infrared area. The funding team totals more than 100 scientific publications, 25 patents and 7 start-up creation (all companies still in operation).

First product on the market is a Point Of Care diagnostic system that delivers result within minutes.

First market targeted is NASH (Non Alcoholic SteatoHepatitis) diagnostic. NASH is a metabolic and inflammatory liver disease linked to overweight. It affects more than 5% of world population, with more than 25% at risk. It is already the second cause for liver transplant in the US, and it has important side effect like diabetes and cardiovascular failures. Its cost has been estimated to $106 Billion per year in the US. Current diagnostic is done using liver biopsy, a highly invasive procedure than is not adapted to mass population screening and follow up.

Biotech developing NASH treatments, that will arrive on the market from 2019, needs noninvasive diagnostic tools, ideally point of care, to be able to detect and treat all affected patients. DIAFIR NASHMIR is currently the only Point Of Care Nash diagnostic tool.